Night of Neurotech
Join us for an evening of networking and breakthrough presentations on the frontier of neuroscience hosted by PsyMed Ventures and E11 Bio. Sponsored by Silicon Valley Bank & Lidow PC.
This year we're featuring founders & scientists exploring far-future neuroscience tech for human augmentation. Neuroscience isn't just for healing; it will elevate everyone's lives.
Speakers:
Ying-Hui Fu, PhD is a Professor of Neurology at UCSF and a world leader in the genetics of sleep. Her lab has discovered the first-known genes behind “natural short sleepers”. Her work bridges human genetics and neuroscience to uncover how to modulate sleep for brain health, aging, and neurodegenerative disease.
Nathalie Gouailhardou is the co-founder and CEO of Neurode, a neurotechnology startup developing a wearable headset to improve focus, impulse control & memory. With a background in neuroscience and research experience at UNSW and the Bionics Institute, Nathalie combines personal experience with ADHD and scientific insight to create accessible, drug-free tools for cognitive health.
Laura Deming is the co-founder and CEO of Cradle, a medical hibernation startup working to pause biological time through reversible whole-body cryopreservation. Laura brings deep scientific vision to the frontier of life extension and neuro-resilience.
Rahul Chhabra is the Co-Founder & CEO of a stealth neurotech startup building large-scale BCI models. With a background in mathematics and electrical engineering, he combines deep technical expertise with entrepreneurial experience. Previously, he scaled Hallparty, a student infrastructure startup, to 30+ campuses. Now, he's applying his skills to the frontier of neurotechnology and AI.
Tracy Brandmeyer is the CEO of Cognigenics, a neurobiotech company pioneering RNA-based therapeutics for brain health. She leads the development of non-invasive, intranasal shRNA delivery systems targeting neural pathways—most notably the 5-HT2A serotonin receptor—to treat anxiety, cognitive decline, and memory loss. Under her leadership, Cognigenics’ lead candidate, COG-201, has shown over 100% improvement in memory performance in preclinical models.